Life Sciences Archive » December, 2020

Life Sciences - December, 2020

284 articles

• The Most-Read Legal Industry Guests Of 2020
• How 2020 Changed The Way Companies Go Public
• Arthrex Tells Justices To End IPRs, Kick PTAB To Congress
• Trump's 'Most-Favored Nation' Rule On Drug Prices Blocked
• SEC Urges Blank-Check Companies To Bolster Disclosures
• AbbVie Tells 7th Circ. Asserting Rights Isn't 'Patent Thicket'
• Top 5 Gov't Contracts Of 2020: Year In Review
• A Look At Trademark Law Changes In Congress' Spending Bill
• Storage Tank Co. Wants Out Of Embryo Class Action
• Real Estate Rumors: Comparato, Square Mile, Related
• Zimmer Angles To Knock Out Bias Suit Over Severance
• Canopy Slaps GW With Patent Suit Over Flagship CBD Drug
• A Law Firm's Guide To Producing A Podcast
• UK Litigation Roundup: Here's What You Missed In London
• Trump Assails $900B COVID-19 Relief Bill In Twitter Video
• 5 Highlights As DOJ Depicts Walmart As Opioid Crisis Villain
• Investors Slam Inovio's Bid To Duck COVID-19 Vaccine Suit
• Shkreli Can't Delay January FTC Deposition, NY Judge Says
• PhRMA Urges Full Fed. Circ. To Walk Back New Venue Limits
• Columbia Care To Acquire Green Leaf Medical For $240M
• Late-Night Relief Bill Will Spur Big Changes To IP
• Okla. Says Pot Residency Rules Can't Be Unconstitutional
• Del. Judge Nixes Equity Panel For 'Insolvent' Mallinckrodt PLC
• Pot Co. Wants Ex-Worker, Attys Sanctioned For 'Fruitless' Suit
• 2 Major Digital Health Trends Driven By COVID-19
• What Gov't Contracting Might Look Like Under Biden
• DOJ Sues Walmart Over Opioid Crisis
• 11th Circ. Backs Bayer In Birth Control Stroke Suit
• Eli Lilly Beats Generic Cancer Drug Again At Fed. Circ.
• Cannabis Co. Ayr Enters Fla., NJ With Deals Totaling $391M
• Coronavirus Regulations: A State-By-State Week In Review
• Willkie, Skadden Steer $1.3B PE Sale Of Sparta To Honeywell
• 5 Important E-Discovery Trends And Developments In 2020
• Congress Backs $900B COVID-19 Relief, Gov't Spending Bill
• CORRECTED: Sacklers Saw Litigation Threat As Early As 2007, Creditors Say
• Jury Clears Drug Wholesaler Over Dubious Int'l Shipment
• 16 New Blank-Check Co. IPO Filings Bolster 2021 Pipeline
• EEOC Inks $175K Pact With Pot Retailer In Harassment Case
• Pfizer's COVID-19 Vaccine Wins Race For EU Approval
• Senate Passes Bill To Levy Economic Sanctions For IP Theft
• Missouri's Pot License Cap Kept Intact As Challenge Fizzles
• Biomet Asks Judge To Ax $21M Hip Implant Verdict
• Baker McKenzie, Wachtell Guide Servier's $2B Cancer Biz Buy
• NJ Water Supplier Wants DuPont, Chemours To Fund Cleanup
• Ex-Theranos CEO's Fraud Trial Moved To July Due To Virus
• 2nd Circ. Won't Rehear Suit Over $600M NY Opioid Tax Law
• Ventilator Co. Strikes $40.5M Deal To End Feds' Fraud Suit
• Judges On Race: The Path To A More Diverse Bench
• DEA Issues Rule To Boost Research Cannabis Cultivation
• Bayer, MSN Labs Seek To Drop Drug IP Fight Midtrial
• No Preemption In Blood Pressure Drug Contamination MDL
• Biotech CEO Charged With Pushing Fake Fast COVID-19 Test
• Goodwin-Led Lab Device Maker's Shares Soar In $130M IPO
• 3rd Circ. Seeks NJ High Court Input In Pelvic Mesh Fees Fight
• 1st Circ. Backs Biogen's Win In Scientist's Disability Bias Suit
• FDA Approves Moderna COVID-19 Vaccine For Emergency Use
• Insurer Lost Millions In Regeneron Drug Scheme, Suit Says
• Calif. Opioid Judge Wary Of Atty Burnout Amid Pandemic
• Compulsory Licensing To Cut Drug Costs Could Harm Public
• Initial Census, Data Analytics Can Aid MDL Management
• A Look At Contrasting Rules For Excess Insurance Policies
• Taxation With Representation: Freshfields, Wachtell, Simpson
• S&C, Greenberg Drive $2.8B Deal For Medical Device Co.
• Full Fed. Circ. Won't Take Up Biogen Appeal Over MS Drug
• Pfizer Faces 1st Damages Trial In 2021 Over Axed Lyrica IP
• 5 Big Developments That Shaped The PTAB In 2020
• 'Killer' Deals, Internet Mergers Caught Enforcers' Eyes In 2020
• Fed. Circ. Won't Revive Patent Suit Over Gallbladder Drug
• FDA Panel Backs Moderna's COVID-19 Vaccine
• Facing Congress' Ire, Sacklers Deflect Blame For Opioid Crisis
• SEC Says Biotech Co. Duped Investors Over COVID-19 Tests
• Monsanto, BASF Plan Appeal Of $75M Dicamba Ruling
• EpiPen Trial Not Feasible Nor Prudent Amid Virus, Judge Says
• Ohio Justices Take Up Acuity's Opioid Suit Coverage Fight
• Year In Review: How Cannabis Law Fared In 2020
• Ex-Indivior Exec Dodges Prison In Suboxone Opioid Case
• J&J Hit With Workplace Bias Suit By Fired Female Exec
• How New Kickback Rules Benefit Health Care Industry: Part 2
• Gilead Says Overbroad Patent Doesn't Need Justices' Review
• Priest Seems Destined For Trial In SEC Short-Selling Suit
• Novartis To Buy Neuroscience Therapy Biz For Up To $770M
• Blackstone's Investment Values Software Co. Over $2B
• Biogen To Pay $22M To Resolve Drug Kickback Claims
• Red White & Bloom Borrows $60M, Buys Ill. Pot Grow Assets
• The 10 Biggest Patent Rulings Of 2020
• Top 10 Whistleblowing And Retaliation Events Of 2020
• ITC Orders Import Ban For Botox Rival In Trade Secrets Case
• Generics 'Urgently' Call On Fed. Circ. To Protect Skinny Labels
• Fintech Lender, Biotech Startup Price IPOs Totaling $429M
• Mallinckrodt Says Market Bodes Ill For Ch. 11 Equity Salvage
• Bausch Accuses Lupin Of Infringing Plenvu Patents
• Express Scripts Says Bad Jury Instructions Led To $82M Loss
• Ex-Theranos CEO, Feds Spar Over Atty-Client Privilege
• How New Kickback Rules Benefit Health Care Industry: Part 1
• The Top Product Liability Cases Of 2020
• Eli Lilly Should Face IP Suit Over Migraine App, Judge Says
• US Attorney In Ohio To Step Down In January
• J&J Elmiron Suits Sent To NJ Federal Court
• FDA, USPTO Data Show Earlier Small-Molecule Drug Patenting
• Feds Say Hospital Illegally Made Nurses Help With Abortions
• Sanofi Asks 5th Circ. To Toss Chemo Drug Hair Loss Claims
• Senate OKs Bill To Expand Research On Medical Cannabis
• COVID-19 Has Broad Impact On Lost-Profit Determinations
• After A Year's Wait, Fed. Circ. Simply OKs Biogen's PTAB Loss
• Quest Wants 'Threadbare' ERISA Class Action Tossed
• Tips For Identifying A Culturally Competent Mediator
• Mallinckrodt Stockholders Face Slim Chance Of Ch. 11 Payout
• Judge Allows Bio-Rad To Collect $35M IP Judgment
• DOJ Opioid Leader Flays Pharmacies In Enforcement Vow
• Zantac MDL Defendants Argue Claims Are Preempted
• Juno Tells Fed. Circ. To Uphold Its $1.2B Patent Win Over Kite
• 3rd Circ. Doubts Par's Exclusive Deal Is Anti-Competitive
• Prepare For More Electronic Device Searches At US Borders
• Coronavirus Regulations: A State-By-State Week In Review
• Trump's 'Most-Favored Nation' Rule Faces More Lawsuits
• A Look At Spoliation Risk In The 11th Circ., By The Numbers
• Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit
• Mapping The Contours Of PTAB Discretionary Denials In 2020
• 3 Firms Guide $1B Lilly Deal For ALS Drug Researcher
• Pa. Sanofi Workers Sue Over Unkept Hazard Pay Pledge
• Del. Justices Affirm Chemours-DuPont Arbitration Ruling
• Lloyd's, Tech Co. Launch Virus Vaccine Transport Cover
• Baker Botts Scores IP Partner From Sidley Austin In Calif.
• Mallinckrodt's Ch. 11 Fee Payout Proposal Rejected
• Karyopharm Execs Hit With Investor Suit Over Cancer Drug
• Drugmakers Call Zantac MDL 'Shotgun Pleadings'
• DLA Piper-Led Gene Therapy Co. Scores $100M In Funding
• Walgreens Goes After Generic Cos. Over Alleged Price-Fixing
• Biotech's Former Brass Fights SEC Efforts To Get Court Wins
• J&J Prevails In Tenn. Woman's Pelvic Mesh Suit At 6th Circ.
• Insurer Wants No Part Of $20M Judgment In Akorn Meds Suit
• E-Commerce Giant Wish To Lead 11 IPOs In Year's Final Rush
• 2 Sacklers To Testify On Purdue's Role In Opioid Crisis
• Facebook, BigLaw Attys Discuss Increasing Diversity In IP
• Justices Won't Review Cochlear's $268M Hearing Aid IP Loss
• Medical Pot Exec Sues Missouri Over License Residency Rule
• High Court Passes On Atty's Stock Fraud Appeal, Again
• Simpson, Skadden Build $3.45B Deal For Lab Office Portfolio
• Freshfields, Wachtell Drive $39B AstraZeneca-Alexion Deal
• Millions Of Health Care Workers Set To Get COVID-19 Vaccine
• Allergan Must Face FCA Claims Over Dementia Drug Patents
• Del. Chief Urges Creativity When Litigating Patent Eligibility
• Judges Stoll, Albright Dish On Litigating During COVID-19
• Chinese National Admits Stealing Lab Trade Secrets With Wife
• Senate Passes Bills On Drug Patent Listings
• IP Owners Have Usually Found Ally In Trump Administration
• A Closer Look At High Court Schein Carveout Case Arguments
• Insurer Can't Yet Dodge Defending Surgical Co. In J&J Suit
• RJ Reynolds Says FDA Cigarette Warnings Flout Free Speech
• Foley Hoag Lures Trade Secret Pro To Lead NY Employment Team
• Misguided Sensipar Ruling Threatens Patent Settlements
• Risks In Moving Too Quickly, Or Slowly, On COVID-19 Vaccine
• Celgene, Cipla Resolve Patent Claims Over Cancer Drug
• No Need To Explain Strategy In Doc Demand, Del. Justices Say
• Fast COVID-19 Vaccines Raise Call For More Collaboration
• AbbVie As Both Victim And Villain Dooms Kickback Suit
• SC Republicans File Medical Marijuana Legalization Bills
• 1st Circ. OKs $763K Retaliation Verdict Against Coloplast
• 10X Calls Fraud In Latest Effort To Dodge $24M Jury Verdict
• Judge Awards Attys $6M In Fees In Intuniv Antitrust Suit
• Coronavirus Litigation: The Week In Review
• Fed. Circ. Again Says No State Sovereign Immunity In IPRs
• Still No WTO Agreement On COVID-19 IP Waiver
• Fed. Claims Judge Tosses Okla. Tribe's 'Bad Men' Opioid Suit
• FDA Panel Backs Emergency Use For Pfizer COVID-19 Vaccine
• Deals Rumor Mill: Robinhood, ChemChina, Omnicell
• HHS Working Group Could Take FCA Pressure Off Health Cos.
• Opioid Committee Wants Claim Deadline In Mallinckrodt Ch. 11
• Life Sciences Group Of The Year: Gibson Dunn
• 4 Firms Steer Gilead's €1.45B Deal For Germany's MYR
• High Court Gives States Green Light To Regulate PBMs
• 9th Circ. Revives ACA Claims Over Access To CVS HIV Drugs
• Ex-Nanotech CEO Accused Of $12.2M Securities Fraud Scam
• Mallinckrodt Opioid Claimants Want OK For Info Website
• Perrigo Must Share Atty Advice Over $2B Tax Bill, Court Rules
• Hagens Berman To Lead Investors' COVID-19 Vaccine Suit
• Generics Partner Tells Justices It Can Appeal PTAB Ruling
• Roche Calls Meso's Bouchard-Related Bias Claims 'Weak'
• Fed. Circ. Judge Skeptical Amgen Cholesterol Drug IP Is Valid
• Startup Artio Medical Nabs New GC From Pet Pharma Co.
• HHS Alert Is Pharma's Guide To Mitigating Anti-Kickback Risk
• COVID-19 Spurs Associates To Think Bigger — Like Partners
• Life Sciences Group Of The Year: Dechert
• Argentinian Polo Star Sues Company Cloning His Horses
• House Approves Medical Marijuana Research Bill
• Zoll Medical Can't Escape Defibrillator Defect Death Suit
• Canada Backs Pfizer Virus Vaccine, Day Before FDA Meeting
• Endobotics Wins $192M In IP Dispute Over Surgical Device
• Pfizer, BioNTech Vaccine Docs Exposed In EU Regulator Hack
• Faruqi & Faruqi Replaces Pomerantz In Allergan Suit
• AbbVie Wants Allergan Merger Docs Out Of Opioid MDL
• Fed. Circ. Mulls Undoing Mylan Win In Biogen Drug IP Fight
• Oklahoma Backs $465M Opioid Win Against J&J
• Objector Challenges Bernstein Litowitz's $11M Fee At 7th Circ.
• Dental Co. Faces Scrutiny From High Court In Carveout Case
• City Tells Miss. Justices To Invalidate Medical Pot Measure
• Par Sues Generic Cos. Over Blood Pressure Drug
• Life Sciences Group Of The Year: Covington
• Coronavirus Regulations: A State-By-State Week In Review
• Congress Should Restore Coarse Filter For Patent Eligibility
• 2nd Circ. Tosses Claims Over Bayer's Mirena Implant
• GCs Are Uniquely Qualified To Lead Diversity Initiatives
• Big Pharma Slams 'Most-Favored Nation' Rule On Drug Prices
• Ex-Theranos CEO Claims Doc Privilege Via Boies Schiller
• Feds Ask 1st Circ. To Reinstate Full Insys Kickback Verdict
• Full Fed. Circ. Urged To Undo Hatch-Waxman Venue Limits
• Feds Call Walmart Preemptive Opioid Suit Improper
• COVID-19 Vaccines Unlikely To Create Litigation Opportunities
• Life Sciences Group Of The Year: Cohen Milstein
• 3 Ways Defendants Can Nip Civil RICO Claims In The Bud
• Another Opioid Bellwether Delayed For COVID-19
• NJ Justices Clear J&J Of Taxes On Coverage Beyond State
• Calif. AG Becerra Selected To Head HHS In Biden Era
• EU Clears DIC's €985M Deal For BASF Pigment Unit With Fix
• Pfizer Unit Gets 'Put Up' Order In Osteoarthritis IP Fight
• 2020's Top Pa. Employment Law Changes, And What's Ahead
• 2nd Circ. Backs Anthem, Express Scripts ERISA Victory
• Biden To Pick Calif. AG Xavier Becerra To Head HHS
• Judges On Race: Reducing Implicit Bias In Courtrooms
• Sens. Back PTAB Denial Rules, Drug Pricing Activists Balk
• Mylan Rival Can Sleep Easy On Insomnia Drug Patent
• FTC Says Likely Pay-For-Delay Deals Remain Few
• Ind. Panel Affirms Medtronic's $112M Loss In IP Contract Row
• 'Lifesaving' Claim Barred In Hernia Mesh Bellwether Trial
• Regeneron Can't Escape Feds' Medicare Kickback Case
• What Health Attys Are Bracing For As Virus Rages Nationwide
• Drug Co. Ex-CEO Liable For $1M FBAR Penalty
• 3rd Circ. Won't Rethink Nixing $448M AbbVie Penalty
• Former Exec Says Zimmer Had 'Figurative Gun To Her Head'
• 3 Biotech Cos. Raise $543M In Upsized Nasdaq Debuts
• California's Cannabis Delivery Law Is Clearer Than It Seems
• Life Sciences Group Of The Year: Arnold & Porter
• UK Litigation Roundup: Here's What You Missed In London
• Justices Warned Of 'Chaos' If They Dismantle AIA Reviews
• Patent Office Loses Stay Bid In PTAB Denials Challenge
• JPML Urged To Ship Elmiron Eye Damage Suits To NJ
• DHS, IBM Warn Of Phishing Bids Targeting Vaccine Delivery
• After Ballot Wins, Pot Faces Long Road To Launch In 5 States
• W.Va. Opioid Bellwether Delayed By Virus Concerns
• Female Judge Should Hear IUD Cases, JPML Told
• SEC Nets $9.8M From AWOL Sanofi Insider Trading Suspect
• DOJ Backs SmileDirect's Calif. Dental Board Case At 9th Circ.
• Vivus Cleared For Amended Ch. 11 Plan With Drug Royalties
• Minn. City Has Right To Ban Flavored Cigs, 8th Circ. Told
• Dueling Attys Call For Xyrem MDL To Be Moved To CA Or NJ
• DEA Faces Another Suit Over Stalled Pot Research
• Siemens, Former Employee Put End To Trade Secret Row
• Next Steps For Now-Legal Mississippi Medical Marijuana
• Navigating Atty Relationship Conflicts That May Imperil Cases
• Tech Titans Fight USPTO's Stay Bid In PTAB Denials Suit
• Ex-Insys Manager Avoids Prison For Opioid Kickback Scheme
• Don't Let Virus Delay W.Va. Opioid Bellwether, Court Urged
• Teva Says Fed. Circ. Made Skinny Label Law 'A Dead Letter'
• Bill To Boot Chinese Cos. From US Exchanges Sent To Trump
• Abbott Can't Escape Infringement Claims Over HIV Testing
• Biopharm Biz Buries Hatchet Over Parkinson's Drug For $7.5M
• Theranos Judge Says Virus Won't Delay Ex-CEO's March Trial
• Fla. Pharmacy Gets Chance To Prove Case Against McKesson
• Bernstein Litowitz Attys Fight Sanctions Bid In Stericycle Case
• Bad Jury Instructions Tainted Med Mal Trial, Pa. Justices Told
• DuPont Rips Chemours' 'Strange' Bid To Void Chancery Ruling
• JLL Guides Sidra's $225M Recapitalization Of Pa. Campus
• Del. Judge Keeps Alive Stanford IP Suits Over Kidney Test
• 2020 Election May Mark A Turning Point For Marijuana Law
• 5 Tips For Responding To Alice Patent Eligibility Rejections
• How Mediators Can Help Parties Overcome Emotional Barriers
• UK Backs Pfizer's Virus Vaccine As US Decision Looms
• In Opioid MDL, Fears Of Allergan Dissolving To Avoid Payout
• Del. Judge Finds Teva Infringed ADHD Drug IP On Remand
• GAO Rips Trump Admin. On COVID-19 Testing, Vaccine Plan
• Biosimilars Group Pushes For Medicine Access Measures
• DC Circ. Upholds FDA Rule Treating Vaping Like Tobacco
• Polsinelli Adds 2 Patent Pros To Miami Office
• Clinics Barred From Gilead HIV Drug Program For Now
• Shearman-Led Medical Device Co. Inks $800M Drug Biz Sale
• Coronavirus Regulations: A State-By-State Week In Review
• OB/GYN Says Immunity Won't Fly In Tribal Hospital Firing Suit
• NJ Justices Doubt Medical Pot Reimbursement Is Illegal
• High Court May Clarify Key Arbitration Issue
• High Court Could Expand FCA Reach In Resolving Circuit Split
• Moderna, Pfizer Playing The Long Game With Novel Vaccine IP
• Generic Co. Gets Horizon's Painkiller Patent Partly Axed
• Biotech Co. Says Rival Stole Trade Secrets In 'Brazen Fraud'
• Judging A Book: Wardlaw Reviews 'Hamilton And The Law'